Goldman Sachs analyst Asad Haider assumed coverage of Merck (MRK) with a Buy rating and price target of $103, down from $129. Following the recent selloff, the shares are now trading at levels ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 11, 2025. REUTERS/Brendan McDermid Wall Street posted solid gains on Friday as big banks kicked off ...

SEC Filings provided by EDGAR Online, Inc.